Shanghai Shen Lian Biomedical Corporation Sustainability Profile
Shanghai Shen Lian Biomedical Corporation, often referred to as Shen Lian Bio, is a prominent player in the biotechnology industry, headquartered in Shanghai, China. Founded in 2005, the company has established itself as a leader in the development and production of innovative biopharmaceuticals and diagnostic products, primarily serving the Asian market. Shen Lian Bio focuses on core areas such as monoclonal antibodies, recombinant proteins, and in vitro diagnostic reagents. Their unique approach combines cutting-edge technology with rigorous quality control, ensuring high efficacy and safety in their offerings. The company has achieved significant milestones, including various certifications and partnerships that enhance its market position. With a commitment to advancing healthcare solutions, Shanghai Shen Lian Biomedical Corporation continues to make strides in the biopharmaceutical sector, contributing to improved patient outcomes and solidifying its reputation as a trusted name in biotechnology.
DitchCarbon Score
How does Shanghai Shen Lian Biomedical Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shanghai Shen Lian Biomedical Corporation's score of 20 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shanghai Shen Lian Biomedical Corporation's reported carbon emissions
Shanghai Shen Lian Biomedical Corporation, headquartered in China, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that the corporation may not have established formal commitments to address carbon emissions or climate change initiatives at this time. As such, the company appears to be in the early stages of developing its climate strategy within the broader context of the biomedical industry.
How Carbon Intensive is Shanghai Shen Lian Biomedical Corporation's Industry?
How Carbon Intensive is Shanghai Shen Lian Biomedical Corporation's Location?
Shanghai Shen Lian Biomedical Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shanghai Shen Lian Biomedical Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
